|
|
.
See Category: Factors influencing health status and contact with health services
See Header: Genetic susceptibility to malignant neoplasm
ICD-10 (CM) Code and Descriptor
|
Z15.01 |
Genetic susceptibility to malignant neoplasm of breast
This code is considered unacceptable as a principal diagnosis.
|
Z1501 utilizaton on OPPS claims.*
Primary
ICD10 Code |
ICD10
Position 2 |
ICD10
Position 3 |
ICD10
Position 4 |
ICD10
Position 5 |
ICD10
Position 6 |
ICD10
Position 7 |
ICD10
Position 8 |
ICD10
Position 9 |
ICD10
Position 10 |
| 13.88%
|
21.25%
|
16.95%
|
11.91%
|
8.13%
|
6.17%
|
4.45%
|
3.57%
|
2.86%
|
2.21%
|
* Medicare Part A utilization data is derived from the 100% 2023 Outpatient (Fee-for-Service) Standard Analytical File.
Commonly Associated Procedure Codes for Z15.01*:
| CPT |
Description |
Number of Claims |
Sum Performed |
|
G0463
|
HOSPITAL OUTPT CLINIC VISIT |
2,477
|
2,487
|
|
C8908
|
MRI W/O FOL W/CONT, BREAST, |
1,275
|
1,275
|
|
36415
|
COLL VENOUS BLD VENIPUNCTURE |
997
|
1,000
|
|
85025
|
COMPLETE CBC W/AUTO DIFF WBC |
718
|
718
|
|
80053
|
COMPREHEN METABOLIC PANEL |
689
|
689
|
|
A9585
|
GADOBUTROL INJECTION |
613
|
40,430
|
|
86304
|
IMMUNOASSAY TUMOR CA 125 |
527
|
527
|
|
A9575
|
INJ GADOTERATE MEGLUMI 0.1ML |
424
|
56,690
|
|
82565
|
ASSAY OF CREATININE |
394
|
394
|
|
C8937
|
CAD BREAST MRI |
359
|
361
|
|
G1004
|
CDSM NDSC |
339
|
375
|
|
A9577
|
INJ MULTIHANCE |
287
|
4,224
|
|
Q3014
|
TELEHEALTH FACILITY FEE |
251
|
251
|
|
A9270
|
NON-COVERED ITEM OR SERVICE |
202
|
391
|
|
76830
|
TRANSVAGINAL US NON-OB |
201
|
201
|
|
74183
|
MRI ABD W/O CNTR FLWD CNTR |
197
|
197
|
|
J3010
|
FENTANYL CITRATE INJECTION |
197
|
406
|
|
G0279
|
TOMOSYNTHESIS, MAMMO |
192
|
192
|
|
J2704
|
INJ, PROPOFOL, 10 MG |
190
|
6,228
|
|
77066
|
DX MAMMO INCL CAD BI |
185
|
185
|
* Derived from 100% 2021 Outpatient (Fee-for-Service) Standard Analytical File.
Z15.01 related to the following DRG Codes:
951
|
